| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.0089 | 0.9 |
| mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.9 |
| mRNA | IU1 | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |